Basics Corbus Pharmaceuticals Holdings, Inc. Common Stock Corbus Pharmaceuticals Holdings Inc is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. IPO Date: November 1, 2014 Sector: Healthcare Industry: Biotech Market Cap: $90.55M Activated in VL: True Average Daily Range Avg Daily Range: $0.31 | 3.91% Avg Daily Range (30 D): $0.30 | 4.22% Avg Daily Range (90 D): $0.31 | 4.15% Institutional Daily Volume Avg Daily Volume: 1.3M Avg Daily Volume (30 D): .11M Avg Daily Volume (90 D): .18M Trade Size Avg Trade Size (Sh.): 263 Avg Trade Size (Sh.) (30 D): 63 Avg Trade Size (Sh.) (90 D): 68 Institutional Trades Total Inst.Trades: 430 Avg Inst. Trade: $1.77M Avg Inst. Trade (30 D): $.78M Avg Inst. Trade (90 D): $.78M Avg Inst. Trade Volume: .03M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $2.05M Avg Closing Trade (30 D): $.78M Avg Closing Trade (90 D): $.78M Avg Closing Volume: 39.83K         News May 22, 2025 @ 12:00 PM Corbus Pharmaceuticals to Present at the Jefferies... Source: N/A Jun 1, 2024 @ 2:00 PM SYS6002 (CRB-701) A Next-Generation Nectin-4 Targe... Source: Corbus Pharmaceuticals Holdings, Inc. May 23, 2024 @ 9:05 PM Updated Phase 1 Clinical Data for SYS-6002 (CRB-70... Source: Corbus Pharmaceuticals Holdings, Inc. May 14, 2024 @ 5:32 PM Will Pharma And Healthcare Have Competitive Edge I... Source: Nicolás Jose Rodriguez Apr 24, 2024 @ 8:05 PM Corbus Pharmaceuticals Announces Abstract Accepted... Source: Corbus Pharmaceuticals Holdings, Inc. Financials   TTM Q1 2025 Q4 2024 Basic EPS $-4.2 $-1.39 $-.76 Diluted EPS $-4.2 $-1.39 $-.76 Revenue $ 7.33M $ 1.68M $ 3.55M Gross Profit $ $ $ Net Income / Loss $ -50.29M $ -16.98M $ -9.53M Operating Income / Loss $ -58.87M $ -19.78M $ -12.61M Cost of Revenue $ $ $ Net Cash Flow $ 3.1M $ M $ -2.23M PE Ratio     Splits Feb 14, 2023:   1:30